Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells.

Di Virgilio F, Jiang LH, Roger S, Falzoni S, Sarti AC, Vultaggio-Poma V, Chiozzi P, Adinolfi E.

Methods Enzymol. 2019;629:115-150. doi: 10.1016/bs.mie.2019.07.043. Epub 2019 Sep 3.

PMID:
31727237
2.

Detection of Extracellular ATP in the Tumor Microenvironment, Using the pmeLUC Biosensor.

De Marchi E, Orioli E, Pegoraro A, Adinolfi E, Di Virgilio F.

Methods Mol Biol. 2020;2041:183-195. doi: 10.1007/978-1-4939-9717-6_13.

PMID:
31646489
3.

TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes.

Magistroni R, Mangolini A, Guzzo S, Testa F, Rapanà MR, Mignani R, Russo G, di Virgilio F, Aguiari G.

BMC Nephrol. 2019 Sep 13;20(1):355. doi: 10.1186/s12882-019-1540-6.

4.

The P2X7 Receptor Is Overexpressed in the Lesional Skin of Subjects Affected by Hidradenitis Suppurativa: A Preliminary Study.

Manfredini M, Giuliani AL, Ruina G, Gafà R, Bosi C, Zoppas E, Di Virgilio F, Bettoli V.

Dermatology. 2019 Aug 27:1-8. doi: 10.1159/000502026. [Epub ahead of print]

PMID:
31454821
5.

Role of the P2X7 receptor in in vitro and in vivo glioma tumor growth.

Bergamin LS, Capece M, Salaro E, Sarti AC, Falzoni S, Pereira MSL, De Bastiani MA, Scholl JN, Battastini AMO, Di Virgilio F.

Oncotarget. 2019 Aug 6;10(47):4840-4856. doi: 10.18632/oncotarget.27106. eCollection 2019 Aug 6.

6.

Extreme thrombocytosis in systemic juvenile idiopathic arthritis. A case report.

Iacono A, Sprocati M, Giuliani AL, Di Virgilio F, Borgna-Pignatti C, Maggiore G.

Ital J Pediatr. 2019 Jun 24;45(1):73. doi: 10.1186/s13052-019-0664-4.

7.

Editorial overview: Purinergic P2X receptors in innate immunity and inflammation.

Di Virgilio F, Pelegrín P.

Curr Opin Pharmacol. 2019 Aug;47:141-144. doi: 10.1016/j.coph.2019.05.003. Epub 2019 Jun 12. No abstract available.

PMID:
31200277
8.

P2X7 Receptor Expression in Patients With Serositis Related to Systemic Lupus Erythematosus.

Furini F, Giuliani AL, Parlati ME, Govoni M, Di Virgilio F, Bortoluzzi A.

Front Pharmacol. 2019 Apr 29;10:435. doi: 10.3389/fphar.2019.00435. eCollection 2019.

9.

The P2X7 Receptor Is Shed Into Circulation: Correlation With C-Reactive Protein Levels.

Giuliani AL, Berchan M, Sanz JM, Passaro A, Pizzicotti S, Vultaggio-Poma V, Sarti AC, Di Virgilio F.

Front Immunol. 2019 Apr 12;10:793. doi: 10.3389/fimmu.2019.00793. eCollection 2019.

10.

Amyloid β-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine.

Chiozzi P, Sarti AC, Sanz JM, Giuliani AL, Adinolfi E, Vultaggio-Poma V, Falzoni S, Di Virgilio F.

Sci Rep. 2019 Apr 24;9(1):6475. doi: 10.1038/s41598-019-42931-2.

11.

Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes.

Clapp C, Diaz-Lezama N, Adan-Castro E, Ramirez-Hernandez G, Moreno-Carranza B, Sarti AC, Falzoni S, Solini A, Di Virgilio F.

Acta Diabetol. 2019 Sep;56(9):1031-1036. doi: 10.1007/s00592-019-01343-4. Epub 2019 Apr 13.

PMID:
30982154
12.

Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis.

Zumerle S, Calì B, Munari F, Angioni R, Di Virgilio F, Molon B, Viola A.

Cell Rep. 2019 Apr 2;27(1):1-10.e4. doi: 10.1016/j.celrep.2019.03.011.

13.

Gut microbiota and immunity in common variable immunodeficiency: crosstalk with pro-inflammatory cytokines.

Franza L, Carusi V, Altamura S, Gasbarrini A, Caraffa A, Kritas SK, Ronconi G, Gallenga CE, Di Virgilio F, Pandolfi F.

J Biol Regul Homeost Agents. 2019 Mar-Apr,;33(2):315-319.

PMID:
30942065
14.

Role of the P2X7 receptor in tumor-associated inflammation.

Adinolfi E, De Marchi E, Orioli E, Pegoraro A, Di Virgilio F.

Curr Opin Pharmacol. 2019 Aug;47:59-64. doi: 10.1016/j.coph.2019.02.012. Epub 2019 Mar 25. Review.

PMID:
30921559
15.

The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.

De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E.

Oncogene. 2019 May;38(19):3636-3650. doi: 10.1038/s41388-019-0684-y. Epub 2019 Jan 17.

16.

Extracellular nucleotides and nucleosides as signalling molecules.

Giuliani AL, Sarti AC, Di Virgilio F.

Immunol Lett. 2019 Jan;205:16-24. doi: 10.1016/j.imlet.2018.11.006. Epub 2018 Nov 12. Review.

PMID:
30439478
17.

Extracellular ATP is a danger signal activating P2X7 receptor in a LPS mediated inflammation (ARDS/ALI).

Cicko S, Köhler TC, Ayata CK, Müller T, Ehrat N, Meyer A, Hossfeld M, Zech A, Di Virgilio F, Idzko M.

Oncotarget. 2018 Jul 17;9(55):30635-30648. doi: 10.18632/oncotarget.25761. eCollection 2018 Jul 17.

18.

ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival.

Gilbert SM, Oliphant CJ, Hassan S, Peille AL, Bronsert P, Falzoni S, Di Virgilio F, McNulty S, Lara R.

Oncogene. 2019 Jan;38(2):194-208. doi: 10.1038/s41388-018-0426-6. Epub 2018 Aug 7.

19.

Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes.

Tezza S, Ben Nasr M, D'Addio F, Vergani A, Usuelli V, Falzoni S, Bassi R, Dellepiane S, Fotino C, Rossi C, Maestroni A, Solini A, Corradi D, Giani E, Mameli C, Bertuzzi F, Pezzolesi MG, Wasserfall CH, Atkinson MA, Füchtbauer EM, Ricordi C, Folli F, Di Virgilio F, Pileggi A, Dhe-Paganon S, Zuccotti GV, Fiorina P.

Diabetes. 2018 Oct;67(10):2038-2053. doi: 10.2337/db17-1227. Epub 2018 Jul 31.

20.

Microglia P2X4 receptors as pharmacological targets for demyelinating diseases.

Di Virgilio F, Sarti AC.

EMBO Mol Med. 2018 Aug;10(8). pii: e9369. doi: 10.15252/emmm.201809369. No abstract available.

21.

Extracellular ATP and P2 purinergic signalling in the tumour microenvironment.

Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E.

Nat Rev Cancer. 2018 Oct;18(10):601-618. doi: 10.1038/s41568-018-0037-0. Review.

PMID:
30006588
22.

Macrophage P2X4 receptors augment bacterial killing and protect against sepsis.

Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, Pacher P, Haskó G.

JCI Insight. 2018 Jun 7;3(11). pii: 99431. doi: 10.1172/jci.insight.99431. eCollection 2018 Jun 7.

23.

Modulation of innate and adaptive immunity by P2X ion channels.

Di Virgilio F, Sarti AC, Grassi F.

Curr Opin Immunol. 2018 Jun;52:51-59. doi: 10.1016/j.coi.2018.03.026. Epub 2018 Apr 7. Review.

PMID:
29631184
24.

Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation.

Di Virgilio F, Giuliani AL, Vultaggio-Poma V, Falzoni S, Sarti AC.

Front Pharmacol. 2018 Feb 1;9:39. doi: 10.3389/fphar.2018.00039. eCollection 2018. Review.

25.

The Elusive P2X7 Macropore.

Di Virgilio F, Schmalzing G, Markwardt F.

Trends Cell Biol. 2018 May;28(5):392-404. doi: 10.1016/j.tcb.2018.01.005. Epub 2018 Feb 10. Review.

PMID:
29439897
26.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

27.

ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.

Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, Jandus C, Bontadini A, Redavid A, Salvestrini V, Romero P, Colombo MP, Di Virgilio F, Cavo M, Adinolfi E, Curti A.

Front Immunol. 2017 Dec 22;8:1918. doi: 10.3389/fimmu.2017.01918. eCollection 2017.

28.

The P2X7 receptor: A main player in inflammation.

Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F.

Biochem Pharmacol. 2018 May;151:234-244. doi: 10.1016/j.bcp.2017.12.021. Epub 2017 Dec 27. Review.

PMID:
29288626
29.

Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection.

Amores-Iniesta J, Barberà-Cremades M, Martínez CM, Pons JA, Revilla-Nuin B, Martínez-Alarcón L, Di Virgilio F, Parrilla P, Baroja-Mazo A, Pelegrín P.

Cell Rep. 2017 Dec 19;21(12):3414-3426. doi: 10.1016/j.celrep.2017.11.079.

30.

P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis.

Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata CK, Zissel G, Goldmann T, Lungarella G, Ferrari D, Di Virgilio F, Robaye B, Boeynaems JM, Lazarowski ER, Blackburn MR, Idzko M.

Front Immunol. 2017 Aug 22;8:1028. doi: 10.3389/fimmu.2017.01028. eCollection 2017.

31.

The P2X7 Receptor in Infection and Inflammation.

Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S.

Immunity. 2017 Jul 18;47(1):15-31. doi: 10.1016/j.immuni.2017.06.020. Review.

32.

Use of luciferase probes to measure ATP in living cells and animals.

Morciano G, Sarti AC, Marchi S, Missiroli S, Falzoni S, Raffaghello L, Pistoia V, Giorgi C, Di Virgilio F, Pinton P.

Nat Protoc. 2017 Aug;12(8):1542-1562. doi: 10.1038/nprot.2017.052. Epub 2017 Jul 6.

PMID:
28683062
33.

The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease.

Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata K, Zissel G, Goldmann T, Lungarella G, Ferrari D, Di Virgilio F, Robaye B, Boeynaems JM, Blackburn MR, Idzko M.

Oncotarget. 2017 May 30;8(22):35962-35972. doi: 10.18632/oncotarget.16414.

34.

Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7.

Fantoni ER, Dal Ben D, Falzoni S, Di Virgilio F, Lovestone S, Gee A.

EJNMMI Res. 2017 Dec;7(1):31. doi: 10.1186/s13550-017-0275-2. Epub 2017 Apr 4.

35.

The P2X7 Receptor-Interleukin-1 Liaison.

Giuliani AL, Sarti AC, Falzoni S, Di Virgilio F.

Front Pharmacol. 2017 Mar 16;8:123. doi: 10.3389/fphar.2017.00123. eCollection 2017. Review.

36.

"Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia".

Cavallari M, Ciccone M, Falzoni S, Cavazzini F, Formigaro L, Di Virgilio F, Rotola A, Rigolin GM, Cuneo A.

Leuk Res Rep. 2017 Jan 22;7:11-13. doi: 10.1016/j.lrr.2017.01.002. eCollection 2017.

37.

Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells.

Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di Virgilio F, Pezzi A, Cavo M, Lemoli RM, Curti A.

Oncotarget. 2017 Jan 24;8(4):5895-5908. doi: 10.18632/oncotarget.13927.

38.

Purinergic signalling in autoimmunity: A role for the P2X7R in systemic lupus erythematosus?

Di Virgilio F, Giuliani AL.

Biomed J. 2016 Oct;39(5):326-338. doi: 10.1016/j.bj.2016.08.006. Epub 2016 Oct 27. Review.

39.

Editorial overview: Cancer.

Di Virgilio F, Pinton P.

Curr Opin Pharmacol. 2016 Aug;29:v-vii. doi: 10.1016/j.coph.2016.07.009. Epub 2016 Jul 29. No abstract available.

PMID:
27476753
40.

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G.

Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.

41.

P2X7 targeting inhibits growth of human mesothelioma.

Amoroso F, Salaro E, Falzoni S, Chiozzi P, Giuliani AL, Cavallesco G, Maniscalco P, Puozzo A, Bononi I, Martini F, Tognon M, Di Virgilio F.

Oncotarget. 2016 Aug 2;7(31):49664-49676. doi: 10.18632/oncotarget.10430.

42.

Extracellular purines, purinergic receptors and tumor growth.

Di Virgilio F, Adinolfi E.

Oncogene. 2017 Jan 19;36(3):293-303. doi: 10.1038/onc.2016.206. Epub 2016 Jun 20. Review.

43.

P2RX7: A receptor with a split personality in inflammation and cancer.

Di Virgilio F.

Mol Cell Oncol. 2015 Feb 3;3(2):e1010937. doi: 10.1080/23723556.2015.1010937. eCollection 2016 Mar.

44.

P2 receptors in cancer progression and metastatic spreading.

Di Virgilio F, Falzoni S, Giuliani AL, Adinolfi E.

Curr Opin Pharmacol. 2016 Aug;29:17-25. doi: 10.1016/j.coph.2016.05.001. Epub 2016 May 24. Review.

PMID:
27262778
45.

Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death.

Salaro E, Rambaldi A, Falzoni S, Amoroso FS, Franceschini A, Sarti AC, Bonora M, Cavazzini F, Rigolin GM, Ciccone M, Audrito V, Deaglio S, Pelegrin P, Pinton P, Cuneo A, Di Virgilio F.

Sci Rep. 2016 May 25;6:26280. doi: 10.1038/srep26280.

46.

Assessing Extracellular ATP as Danger Signal In Vivo: The pmeLuc System.

Di Virgilio F, Pinton P, Falzoni S.

Methods Mol Biol. 2016;1417:115-29. doi: 10.1007/978-1-4939-3566-6_7.

PMID:
27221485
47.

A Commentary on "PTX3 is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer".

Di Virgilio F.

Front Oncol. 2015 May 28;5:118. doi: 10.3389/fonc.2015.00118. eCollection 2015. No abstract available.

48.

Purinergic signaling in the immune system.

Di Virgilio F, Vuerich M.

Auton Neurosci. 2015 Sep;191:117-23. doi: 10.1016/j.autneu.2015.04.011. Epub 2015 Apr 30. Review.

PMID:
25979766
49.

The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein.

Franceschini A, Capece M, Chiozzi P, Falzoni S, Sanz JM, Sarti AC, Bonora M, Pinton P, Di Virgilio F.

FASEB J. 2015 Jun;29(6):2450-61. doi: 10.1096/fj.14-268714. Epub 2015 Feb 17.

PMID:
25690658
50.

p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner.

Giorgi C, Bonora M, Sorrentino G, Missiroli S, Poletti F, Suski JM, Galindo Ramirez F, Rizzuto R, Di Virgilio F, Zito E, Pandolfi PP, Wieckowski MR, Mammano F, Del Sal G, Pinton P.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1779-84. doi: 10.1073/pnas.1410723112. Epub 2015 Jan 26.

Supplemental Content

Loading ...
Support Center